Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quassia refers to the wood and extracts from plants of the genus *Quassia*, most notably *Quassia amara* and *Picrasma excelsa*. It is traditionally used as a bitter tonic and stomachic for digestive complaints such as indigestion and loss of appetite. Other suggested uses include treatment for fever, diarrhea, lice infestations (topically), measles, skin conditions, diabetes management (due to its hypoglycemic effect), and as an antifertility agent. The main active constituents are quassinoids (notably quassin) and various alkaloids. Pharmacological studies indicate that Quassia exhibits antibacterial, antifungal, antitumorigenic/insecticidal properties; it also has antiulcer effects likely mediated by inhibition of gastric acid secretion via histamine H2 receptor antagonism[6][8]. Despite these activities in preclinical models or traditional use settings—there is insufficient clinical evidence supporting efficacy for any indication[1][2]. Quassia is generally regarded as safe in food amounts but may cause gastrointestinal irritation or toxicity at higher doses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quassia.